Entities / Company
Tandem Diabetes Care, Inc..
U.S. healthcare company
- Reports this week
- 3
- Active events
- 2
- Connections
- 47
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
One to three months ago
-
Tandem Diabetes Care is awaiting FDA clearance for its tubeless Tandem Mobi system while also expanding pump adoption through new product launches.Some support1 report
-
Bank of America dropped its target price on Tandem Diabetes Care, while TD Cowen reissued a buy rating for the company.Some support1 report
-
Tandem Diabetes Care, Inc., a medical device company, is currently operating in the medical device sector and is subject to analyst reports influencing market sentiment.Some support1 report
Gone quiet
No new reports in 90+ days-
Truist Financial and Citigroup issued ratings and price targets for Tandem Diabetes Care, Inc., with MarketBeat aggregating the data.Some support1 report
-
Tandem Diabetes Care, headquartered in San Diego, operates across the US, Canada, Switzerland, and the Netherlands.Some support2 reports
-
The FDA granted clearance for Tandem Diabetes Care's SteadiSet infusion set.Some support1 report
-
Abbott's sensor system integrates with Tandem's pump, with the Volt system being a key confidence driver.Speculative2 reports
-
Trump's tariff plan caused market tanking, impacting smaller companies in the Russell 2000 index.Some support1 report2 developments inside
-
Tandem Diabetes Care, Hims & Hers Health, and Omnicell are noted as companies operating in the healthcare technology segment.Some support1 report
-
Financial institutions, including Mizuho and UBS, inquired about Tandem Diabetes Care's commercial launch, path to 60% gross margin, and uptake of pump demand.Speculative1 report
-
Tandem Diabetes Care stock was downgraded to Sell on July 10, 2025, following an analyst report from Citibank.Some support2 reports
-
Tandem Diabetes Care initiated an early access program in a country.Speculative1 report
-
Tandem Diabetes Care, Inc. is based in San Diego, California.Some support2 reports
-
Tandem Diabetes Care issued correction notices to impacted customers in the U.S. in August 2025.Some support1 report
-
Tandem Diabetes Care reported 21,000 pump shipments in the United States in August 2025.Some support2 reports
-
Tandem Diabetes Care, Inc. reported Non-GAAP sales in the United States totaled $170.2 million.Some support1 report
-
John Sheridan was appointed president and CEO of Tandem Diabetes Care, Inc.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around Tandem Diabetes Care, Inc. this week
News at the entities that move Tandem Diabetes Care, Inc. most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Tandem Diabetes Care, Inc.
-
Dexcom StructuralOura announces partnerships with Dexcom and Resmed for health feature integration, while noting that regulatory uncertainty affects its product scope.Moves Tandem Diabetes Care, Inc.
-
Truist Financial OperationalMarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.Moves Tandem Diabetes Care, Inc.
-
TD Cowen TransactionalAnalyst downgraded Ag Growth International Inc. due to debt management risks.Moves Tandem Diabetes Care, Inc.
-
Citigroup OperationalCitigroup provided analyst ratings and targets for Autodesk stock, which trades on Nasdaq.Moves Tandem Diabetes Care, Inc.
-
Bank of America Mentioned togetherGoldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Moves Tandem Diabetes Care, Inc.
Connections
The 12 strongest of 47, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Abbott Japan Structural
Tandem integrates Abbott's glucose sensor technology into its pumps to enable broader access to integrated diabetes management systems.
-
FDA Structural
The FDA formally regulates Tandem Diabetes Care's medical devices, requiring product clearance and review for market access.
-
Dexcom Structural
Tandem's medical device product relies functionally on Dexcom's continuous glucose monitoring technology.
-
Truist Financial Operational
Truist Financial has issued a buy rating and price target for Tandem Diabetes Care, Inc.
-
Bank of America Mentioned together
Bank of America provides financial analysis and target price recommendations on Tandem Diabetes Care.
-
TD Cowen Transactional
TD Cowen, a financial services firm, issued a buy rating on Tandem Diabetes Care, Inc.
-
Solventum Operational
Two healthcare companies are actively competing in the market.
-
Citigroup Operational
Citigroup issues financial ratings and price targets for Tandem Diabetes Care, influencing its market perception.
Show all 12 connections
-
MarketBeat Mentioned together
MarketBeat aggregates financial ratings and price targets for Tandem Diabetes Care, Inc.
-
Netherlands Shared context
The company operates within the geographical and market context of the Netherlands.
-
San Diego Shared context
Tandem Diabetes Care, Inc. is headquartered in San Diego, California.
-
Italy Shared context
Tandem Diabetes Care operates and launched products within the market context of Italy.
History
Events by the month they beganSeptember 2026
3 events- Tandem Mobi utilizes Dexcom G7 technology for monitoring.
- Solventum and Tandem Diabetes Care, Inc., two companies in the healthcare sector, are currently facing market comparison.
- Femasys Inc. and Tandem Diabetes Care, Inc., two small-cap healthcare companies, are showing share price volatility compared to the S&P 500.
August 2026
2 eventsShow 1 earlier month
June 2026
14 events- Truist Financial and Citigroup issued ratings and price targets for Tandem Diabetes Care, Inc., with MarketBeat aggregating the data.
- Tandem Diabetes Care, headquartered in San Diego, operates across the US, Canada, Switzerland, and the Netherlands.
- The FDA granted clearance for Tandem Diabetes Care's SteadiSet infusion set.
- Abbott's sensor system integrates with Tandem's pump, with the Volt system being a key confidence driver.
- Trump's tariff plan caused market tanking, impacting smaller companies in the Russell 2000 index.
- Tandem Diabetes Care, Hims & Hers Health, and Omnicell are noted as companies operating in the healthcare technology segment.
- Financial institutions, including Mizuho and UBS, inquired about Tandem Diabetes Care's commercial launch, path to 60% gross margin, and uptake of pump demand.
- Tandem Diabetes Care stock was downgraded to Sell on July 10, 2025, following an analyst report from Citibank.
- Tandem Diabetes Care initiated an early access program in a country.
- Tandem Diabetes Care, Inc. is based in San Diego, California.
- Tandem Diabetes Care issued correction notices to impacted customers in the U.S. in August 2025.
- Tandem Diabetes Care reported 21,000 pump shipments in the United States in August 2025.
- Tandem Diabetes Care, Inc. reported Non-GAAP sales in the United States totaled $170.2 million.
- John Sheridan was appointed president and CEO of Tandem Diabetes Care, Inc.